Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2025-06-05 Capital/Financing Update
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Isofol offentliggör slutliga villkor i företrädesemission samt för en potentiell övertilldelningsemission
Capital/Financing Update Classification · 98% confidence The document is a press release from Isofol Medical AB detailing the final terms of a rights issue ('Företrädesemissionen') and a potential over-allotment issue ('Övertilldelningsemissionen'). It discusses the subscription price, the number of new shares and warrants being issued, the expected capital raised, and the timeline for the transaction, including an upcoming Extraordinary General Meeting (EGM) to approve the issue. This content directly relates to the company's fundraising and capital structure changes. Keywords like 'emission', 'units', 'aktier' (shares), 'teckningsoptioner' (warrants), 'teckningskursen' (subscription price), and the focus on securing financing strongly point towards a Capital/Financing Update. It is not an Annual Report (10-K), an Earnings Release (ER), or an Interim Report (IR) as it focuses on the mechanics of a financing event, not the operational or periodic financial results themselves. It is a specific announcement about capital raising, matching the definition for 'Capital/Financing Update' (CAP).
2025-06-05 Swedish
Isofol announces final terms of the rights issue and the potential overallotment issue
Capital/Financing Update Classification · 99% confidence The document is a press release titled "Isofol announces final terms of the rights issue and the potential overallotment issue." It details the structure, subscription price, timeline, dilution effects, and guarantee commitments for a rights issue (a form of capital raising/financing activity). This clearly falls under the definition of Capital/Financing Update (CAP). Although it mentions an upcoming Extraordinary General Meeting (EGM) to approve the issue, the primary content is the announcement of the final terms of the financing itself, not the results of a vote (DVA) or general AGM materials (AGM-R). It is not a full annual report (10-K) or an interim report (IR).
2025-06-05 English
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21, 2025
AGM Information Classification · 100% confidence The document explicitly states it is a 'Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21, 2025'. It details resolutions passed regarding the adoption of financial statements, election of board members and auditor, approval of remuneration reports, and implementation of incentive programs. These are all core activities and outcomes of an Annual General Meeting (AGM). Therefore, the classification should be AGM-R.
2025-05-21 English
Kommuniké från årsstämma i Isofol Medical AB (publ) den 21 maj 2025
AGM Information Classification · 100% confidence The document is explicitly titled 'Kommuniké från årsstämma i Isofol Medical AB (publ) den 21 maj 2025' (Communiqué from the Annual General Meeting in Isofol Medical AB (publ) on May 21, 2025). It details the key decisions made by the shareholders, including the approval of financial statements, board elections, remuneration decisions, approval of an incentive program, and authorization for new share issues. These are all typical outcomes and announcements following an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R (AGM Information). The document length (5992 chars) is substantial enough to be the primary communication, not just a brief announcement of publication (RPA).
2025-05-21 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI - MARS 2025' (Interim Report January - March 2025) for Isofol Medical AB. It contains comprehensive financial data, including income statements, cash flow, and key performance indicators for the first quarter of 2025, alongside detailed management commentary on clinical trials and business strategy. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2025
2025-05-21 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ISOFOL MEDICAL AB (PUBL) INTERIM REPORT' and covers the period 'JANUARY - MARCH 2025'. It contains detailed financial information, including a table of key figures (Net revenue, Result for the period, Earnings per share, Cash and cash equivalents), as well as management commentary on clinical trials, business strategy, and future outlook. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-05-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.